» Articles » PMID: 35745635

The Diverse Biological Activity of Recently Synthesized Nitro Compounds

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Jun 24
PMID 35745635
Authors
Affiliations
Soon will be listed here.
Abstract

The search for new and efficient pharmaceuticals is a constant struggle for medicinal chemists. New substances are needed in order to treat different pathologies affecting the health of humans and animals, and these new compounds should be safe, effective and have the fewest side effects possible. Some functional groups are known for having biological activity; in this matter, the nitro group (NO) is an efficient scaffold when synthesizing new bioactive molecules. Nitro compounds display a wide spectrum of activities that include antineoplastic, antibiotic, antihypertensive, antiparasitic, tranquilizers and even herbicides, among many others. Most nitro molecules exhibit antimicrobial activity, and several of the compounds mentioned in this review may be further studied as lead compounds for the treatment of and infections, among others. The NO moiety triggers redox reactions within cells causing toxicity and the posterior death of microorganisms, not only bacteria but also multicellular organisms such as parasites. The same effect may be present in humans as well, so the nitro groups can be considered both a pharmacophore and a toxicophore at the same time. The role of the nitro group itself also has a deep effect on the polarity and electronic properties of the resulting molecules, and hence favors interactions with some amino acids in proteins. For these reasons, it is fundamental to analyze the recently synthesized nitro molecules that show any potential activity in order to develop new pharmacological treatments that enhance human health.

Citing Articles

Fungal mediated production of novel metabolites of meloxicam and their tankyrase-2 inhibition potentials: an in silico study.

Keshetti S, Prasad G Int Microbiol. 2025; .

PMID: 40019717 DOI: 10.1007/s10123-025-00636-9.


Photoredox radical/polar crossover enables carbo-heterofunctionalization of alkenes: facile access to 1,3-difunctionalized nitro compounds.

Patra S, Valsamidou V, Nandasana B, Katayev D Chem Commun (Camb). 2025; 61(8):1689-1692.

PMID: 39749586 PMC: 11696862. DOI: 10.1039/d4cc06005a.


Enzyme (α-Glucosidase, α-Amylase, PTP1B & VEGFR-2) Inhibition and Cytotoxicity of Fluorinated Benzenesulfonic Ester Derivatives of the 5-Substituted 2-Hydroxy-3-nitroacetophenones.

Olomola T, Nkoana J, More G, Gildenhuys S, Mphahlele M Int J Mol Sci. 2024; 25(22).

PMID: 39595931 PMC: 11594133. DOI: 10.3390/ijms252211862.


Exploring Acyl Thiotriazinoindole Based Pharmacophores: Design, Synthesis, and SAR Studies with Molecular Docking and Biological Activity Profiling against Urease, α-amylase, α-glucosidase, Antimicrobial, and Antioxidant Targets.

Haider M, Saeed A, Ahmed A, Azeem M, Ismail H, Mehmood S Protein J. 2024; 43(5):1009-1024.

PMID: 39222239 DOI: 10.1007/s10930-024-10229-6.


Molecular Hybrid Design, Synthesis, In Vitro Cytotoxicity, In Silico ADME and Molecular Docking Studies of New Benzoate Ester-Linked Arylsulfonyl Hydrazones.

Ergan E, Cakmak R, Basaran E, Mali S, Akkoc S, Annadurai S Molecules. 2024; 29(15).

PMID: 39124882 PMC: 11313727. DOI: 10.3390/molecules29153478.


References
1.
Olender D, Zwawiak J, Zaprutko L . Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines. Pharmaceuticals (Basel). 2018; 11(2). PMC: 6027522. DOI: 10.3390/ph11020054. View

2.
Divakaran S, Loscalzo J . The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. J Am Coll Cardiol. 2017; 70(19):2393-2410. PMC: 5687289. DOI: 10.1016/j.jacc.2017.09.1064. View

3.
Papadopoulou M, Bloomer W, Rosenzweig H . The antitubercular activity of various nitro(triazole/imidazole)-based compounds. Bioorg Med Chem. 2017; 25(21):6039-6048. DOI: 10.1016/j.bmc.2017.09.037. View

4.
Isa E, Ahmad H, Rahman M, Gill M . Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment. Pharmaceutics. 2021; 13(2). PMC: 7911720. DOI: 10.3390/pharmaceutics13020152. View

5.
Sharma R, Joubert J, Malan S . Recent Developments in Drug Design of NO-donor Hybrid Compounds. Mini Rev Med Chem. 2018; 18(14):1175-1198. DOI: 10.2174/1389557518666180416150005. View